(Q44336355)

English

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

phase II clinical trial

0 references

author name string

A R Abdul Razak

1

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

D Soulières

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

S A Laurie

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

S J Hotte

4

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

S Singh

5

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

E Winquist

6

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

S Chia

7

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

C Le Tourneau

8

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

P-F Nguyen-Tan

9

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

E X Chen

10

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

K K Chan

11

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

T Wang

12

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

N Giri

13

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

C Mormont

14

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

S Quinn

15

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

L L Siu

16

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

28 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

761-769

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Head and neck cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

Molecular targeted therapies in all histologies of head and neck cancers: an update

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

Mechanisms of resistance to HER family targeting antibodies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS503

21 January 2018

Identifiers

10.1093/ANNONC/MDS503

1 reference

https://api.fatcat.wiki/v0/release/32flkhmtmnhbziwypzsxrsxobi

30 July 2022

based on heuristic

mapped directly with Wikidata item

release_32flkhmtmnhbziwypzsxrsxobi

1 reference

https://api.fatcat.wiki/v0/release/32flkhmtmnhbziwypzsxrsxobi

30 July 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

https://api.fatcat.wiki/v0/release/32flkhmtmnhbziwypzsxrsxobi

30 July 2022

based on heuristic

mapped directly with Wikidata item

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44336355&oldid=2109540377"